CVS Health names DeVaney
CVS taps Ed DeVaney to head Caremark
The appointment marks the latest in a spate of leadership changes at CVS as the company’s insurance segment struggles to manage increased medical costs. David Joyner, who previously led Caremark, was named CVS president and CEO in October, replacing previous chief executive Karen Lynch.
Despite a recent 45% rally, I maintain a 'Sell' view on CVS due to its underwhelming execution record and rising leverage ...
After underperforming throughout 2024, shares of CVS Health (NYSE: CVS) are surging. From the end of 2024 through Feb. 14, ...
CVS Health (NYSE:CVS – Free Report) had its price target lifted by JPMorgan Chase & Co. from $80.00 to $81.00 in a report ...
Hosted on MSN2d
CVS Health Post-Q4 Earnings: Is the Stock Worth Buying Now?As healthcare spending continues to rise and regulatory pressure intensifies, companies like CVS Health CVS find themselves ...
CVS Health’s adjusted fourth-quarter profit handily beat Wall Street’s estimates, even as the drugstore chain and pharmacy ...
Blue Trust Inc. decreased its stake in shares of CVS Health Co. (NYSE:CVS – Free Report) by 14.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm ...
CVS Health (CVS) stock soared about 15% yesterday after posting upbeat fourth-quarter results, with revenues and earnings ...
CVS Health Corp (NYSE:CVS) reported fourth-quarter sales of $97.71 billion, beating the consensus of $97.19 billion. Total ...
Equities researchers at Leerink Partnrs increased their Q1 2025 earnings estimates for shares of CVS Health in a research report issued on Wednesday, February 12th. Leerink Partnrs analyst M. Cherny ...
Argus raised the firm’s price target on CVS Health (CVS) to $77 from $68 and keeps a Buy rating on the shares. Despite an uneven performance ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback